Looking at the data it is hard to see how the FDA will not approve this on January 6th under its accelerated review program. The absolute key in my view is that this was conducted across a very wide demographic so this is broad and aggregated data and you are seeing a treatment effect on all cognitive scores from 6 months and the effect is increasing with time and looks to further increase beyond the 18 month trial window.
It looks very likely that with 18 months, we will see a lot of people getting Cognigrams in a healthcare setting.
Ann: Business Update and September 2022 Quarter Cashflow, page-19
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
89.5¢ |
Change
-0.005(0.56%) |
Mkt cap ! $154.5M | |||
| Open | High | Low | Value | Volume |
| 90.0¢ | 90.0¢ | 89.0¢ | $63.98K | 71.53K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7155 | 89.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 4760 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| CGS (ASX) Chart |